Bank of the West’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $6.5M | Buy |
75,700
+15,667
| +26% | +$1.24M | 0.76% | 34 |
|
|
2022
Q3 | $3.7M | Buy |
60,033
+4,071
| +7% | +$257K | 0.48% | 60 |
|
|
2022
Q2 | $3.46M | Buy |
55,962
+677
| +1% | +$41.9K | 0.44% | 63 |
|
|
2022
Q1 | $3.29M | Buy |
55,285
+3,582
| +7% | +$229K | 0.34% | 82 |
|
|
2021
Q4 | $3.75M | Buy |
51,703
+742
| +1% | +$51.1K | 0.36% | 79 |
|
|
2021
Q3 | $3.56M | Buy |
50,961
+5,512
| +12% | +$387K | 0.37% | 75 |
|
|
2021
Q2 | $3.13M | Buy |
45,449
+1,067
| +2% | +$71.2K | 0.32% | 85 |
|
|
2021
Q1 | $2.87M | Sell |
44,382
-20,390
| -31% | -$1.31M | 0.32% | 82 |
|
|
2020
Q4 | $3.77M | Buy |
64,772
+3,457
| +6% | +$209K | 0.44% | 61 |
|
|
2020
Q3 | $3.87M | Sell |
61,315
-8,635
| -12% | -$599K | 0.52% | 52 |
|
|
2020
Q2 | $5.38M | Buy |
69,950
+9,555
| +16% | +$732K | 0.73% | 36 |
|
|
2020
Q1 | $4.52M | Sell |
60,395
-19,111
| -24% | -$1.32M | 0.7% | 40 |
|
|
2019
Q4 | $5.17M | Sell |
79,506
-2,048
| -3% | -$133K | 0.61% | 47 |
|
|
2019
Q3 | $5.17M | Buy |
81,554
+1,774
| +2% | +$116K | 0.62% | 43 |
|
|
2019
Q2 | $5.39M | Buy |
79,780
+2,065
| +3% | +$136K | 0.63% | 42 |
|
|
2019
Q1 | $5.05M | Buy |
77,715
+7,076
| +10% | +$470K | 0.59% | 46 |
|
|
2018
Q4 | $4.42M | Sell |
70,639
-5,182
| -7% | -$362K | 0.53% | 53 |
|
|
2018
Q3 | $5.85M | Sell |
75,821
-1,109
| -1% | -$83.8K | 0.69% | 40 |
|
|
2018
Q2 | $5.45M | Buy |
76,930
+948
| +1% | +$66.9K | 0.67% | 42 |
|
|
2018
Q1 | $5.73M | Sell |
75,982
-8,599
| -10% | -$684K | 0.72% | 38 |
|
|
2017
Q4 | $6.06M | Sell |
84,581
-1,719
| -2% | -$131K | 0.76% | 40 |
|
|
2017
Q3 | $6.99M | Buy |
86,300
+1,601
| +2% | +$122K | 0.88% | 32 |
|
|
2017
Q2 | $6M | Sell |
84,699
-18,623
| -18% | -$1.24M | 0.77% | 36 |
|
|
2017
Q1 | $7.02M | Sell |
103,322
-51
| -0% | -$3.59K | 0.88% | 29 |
|
|
2016
Q4 | $7.4M | Sell |
103,373
-19,497
| -16% | -$1.45M | 1.03% | 21 |
|
|
2016
Q3 | $9.72M | Buy |
122,870
+9,845
| +9% | +$800K | 1.34% | 14 |
|
|
2016
Q2 | $9.43M | Buy |
113,025
+6,750
| +6% | +$599K | 1.34% | 11 |
|
|
2016
Q1 | $9.76M | Buy |
106,275
+3,354
| +3% | +$302K | 1.35% | 15 |
|
|
2015
Q4 | $10.4M | Buy |
102,921
+7,112
| +7% | +$740K | 1.45% | 10 |
|
|
2015
Q3 | $9.41M | Sell |
95,809
-1,970
| -2% | -$219K | 1.5% | 7 |
|
|
2015
Q2 | $11.4M | Sell |
97,779
-1,277
| -1% | -$140K | 1.63% | 7 |
|
|
2015
Q1 | $9.72M | Buy |
99,056
+14,751
| +17% | +$1.5M | 1.37% | 12 |
|
|
2014
Q4 | $7.95M | Buy |
84,305
+223
| +0.3% | +$23.1K | 1.16% | 18 |
|
|
2014
Q3 | $8.95M | Sell |
84,082
-572
| -0.7% | -$56K | 1.52% | 11 |
|
|
2014
Q2 | $7.02M | Buy |
84,654
+3,017
| +4% | +$235K | 1.09% | 21 |
|
|
2014
Q1 | $5.79M | Buy |
81,637
+391
| +0.5% | +$30.7K | 0.95% | 31 |
|
|
2013
Q4 | $6.1M | Sell |
81,246
-4,539
| -5% | -$316K | 0.97% | 27 |
|
|
2013
Q3 | $5.39M | Sell |
85,785
-7,000
| -8% | -$418K | 0.98% | 29 |
|
|
2013
Q2 | $4.76M | Buy |
+92,785
| New | +$4.84M | 0.89% | 36 |
|
Other funds holding GILD
Bank of the West's GILD Position: Q4 2022 in Review
Bank of the West increased its Gilead Sciences (GILD) stake by 26% in Q4 2022, buying an estimated $1.24M and bringing the position to 75,700 shares worth $6.5M. The position accounts for 0.76% of the portfolio, ranked #34.
Bank of the West first reported a position in GILD in Q2 2013 and has held it in 39 quarters since. The position peaked at $11.4M in Q2 2015. 1,768 funds tracked by Wall St. Rank hold GILD as of Q4 2022.
- Bank of the West held 75,700 shares of Gilead Sciences worth $6.5M as of Q4 2022.
- Bank of the West bought 15,667 Gilead Sciences shares in Q4 2022, an estimated $1.24M.
- Gilead Sciences made up 0.76% of Bank of the West's portfolio in Q4 2022, its #34 holding.
- Bank of the West first reported a position in Gilead Sciences in Q2 2013 and has held it in 39 quarters since.
- Bank of the West's Gilead Sciences position peaked at $11.4M in Q2 2015.
- 1,768 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.
Based on Bank of the West's 13F filing for Q4 2022, filed 1 Feb 2023.